GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entasis Therapeutics Holdings Inc (NAS:ETTX) » Definitions » Operating Margin %

Entasis Therapeutics Holdings (Entasis Therapeutics Holdings) Operating Margin % : 0.00% (As of Mar. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Entasis Therapeutics Holdings Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Entasis Therapeutics Holdings's Operating Income for the three months ended in Mar. 2022 was $-15.26 Mil. Entasis Therapeutics Holdings's Revenue for the three months ended in Mar. 2022 was $0.00 Mil. Therefore, Entasis Therapeutics Holdings's Operating Margin % for the quarter that ended in Mar. 2022 was 0.00%.

The historical rank and industry rank for Entasis Therapeutics Holdings's Operating Margin % or its related term are showing as below:


ETTX's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -171.86
* Ranked among companies with meaningful Operating Margin % only.

Entasis Therapeutics Holdings's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Entasis Therapeutics Holdings's Operating Income for the three months ended in Mar. 2022 was $-15.26 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2022 was $-51.71 Mil.


Entasis Therapeutics Holdings Operating Margin % Historical Data

The historical data trend for Entasis Therapeutics Holdings's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entasis Therapeutics Holdings Operating Margin % Chart

Entasis Therapeutics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Operating Margin %
Get a 7-Day Free Trial - -657.40 -637.66 - -

Entasis Therapeutics Holdings Quarterly Data
Dec16 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Entasis Therapeutics Holdings's Operating Margin %

For the Biotechnology subindustry, Entasis Therapeutics Holdings's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entasis Therapeutics Holdings's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entasis Therapeutics Holdings's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Entasis Therapeutics Holdings's Operating Margin % falls into.



Entasis Therapeutics Holdings Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Entasis Therapeutics Holdings's Operating Margin % for the fiscal year that ended in Dec. 2021 is calculated as

Operating Margin %=Operating Income (A: Dec. 2021 ) / Revenue (A: Dec. 2021 )
=-47.154 / 0
= %

Entasis Therapeutics Holdings's Operating Margin % for the quarter that ended in Mar. 2022 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2022 ) / Revenue (Q: Mar. 2022 )
=-15.256 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Entasis Therapeutics Holdings  (NAS:ETTX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Entasis Therapeutics Holdings Operating Margin % Related Terms

Thank you for viewing the detailed overview of Entasis Therapeutics Holdings's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Entasis Therapeutics Holdings (Entasis Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
35 Gatehouse Drive, Waltham, MA, USA, 02451
Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas).
Executives
Theravance Inc 10 percent owner 1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Kristie Ann Wagner officer: VP, Principal Fin & Acct Off 35 GATEHOUSE DRIVE WALTHAM MA 02451
David Altarac officer: Chief Medical Officer 35 GATEHOUSE DRIVE WALTHAM MA 02451
Michael Gutch officer: Chief Fin. and Bus. Officer C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
John Patrick Mueller officer: Chief Development Officer C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Manoussos Perros director, officer: President and CEO C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Ruben Tommasi officer: Chief Scientific Officer C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Matthew Ronsheim officer: See Remarks 35 GATEHOUSE DRIVE WALTHAM MA 02451
Elizabeth M Keiley officer: General Counsel C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Anna Diaz Triola officer: Chief Commercial Officer 35 GATEHOUSE DRIVE WALTHAM MA 02451
Innoviva Strategic Opportunities Llc director, 10 percent owner 1209 ORANGE STREET, WILMINGTON DE 19801
Eric Wilson Kimble officer: Chief Commercial Officer C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Frazier Life Sciences Viii, L.p. 10 percent owner 601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Howard Mayer director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Heather Behanna director C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451